The Translational and Early Phase Radiotherapy Trials Hub provides the support and translational research expertise to integrate biomarker science into the development of phase one feasibility studies. We do this in collaboration with Prof. Caroline Dive at the CRUK Manchester Institute Cancer Biomarker Centre, the Experimental Cancer Medicine Team (ECMT), The Geoffrey Jefferson Brain Research Centre, and working closely with the other RadNet themes.
At a Glance: Translational and Early Phase Radiotherapy Trials Hub
This hub focuses on integrating biomarker science into the development of phase 1 feasibility trials using radiotherapy plus a combined modality. Leveraging infrastructure and expertise provided by the Cancer Biomarkers Centre, and Experimental Cancer Medicine Centre at The Christie, researchers can drive forward novel radiotherapy combination clinical trials, technical radiotherapy trials and imaging trials that relate to radiotherapy. Standardisation of translational methods across centres is important to facilitate collaboration, data sharing and validation, therefore researchers are working towards standardisation of protocols for sample collection, processing and analysis of cfDNA as an early indicator of radiotherapy toxicity and response.
Projects being worked on in this hub include:
- The POBIG Study – a flagship early phase study that will test the safety and feasibility of a single fraction radiotherapy pre-operatively in patients with glioblastoma.
- Bio-CHECC – which aims to develop and test hypoxia biomarkers in women with cervical cancer
- CRAIN – a Phase 1b trial of a new drug-chemoradiotherapy combination in cervix cancer.
Research Questions: Translational and Early Phase Radiotherapy Trials Hub
By working with other researchers across Manchester, our researchers are seeking to answer key questions that will help improve the translation of pre-clinical studies into early phase clinical trials. Examples of the research questions being addressed through this theme include:
- Investigate liquid biomarkers associated with response and toxicity through current and future early phase radiotherapy and translational studies.
- Studying liquid biopsies and tissue samples to facilitate rapid transition to national/ international biomarker driven trials.
- Identify unique translational opportunities resulting from novel RT protocols.
About CRUK RadNet Manchester
Cancer Research UK RadNet Manchester is a Radiation Research Unit in collaboration with The Christie
RadNet Facilities and Infrastructure
CRUK RadNet Manchester benefits from the existing infrastructure and facilities within Manchester across the various strategic partners of the CRUK Manchester Centre.
AHP Doctoral Academy
Providing training and development for Allied Health Professionals (AHPs) including radiographers.
Radiotherapy and Immune Cell Interactions
Discover research investigating the immunological consequences of radiotherapy, including immunotherapy and radiotherapy combinations.
Treating Complex Comorbid Patients
Discover how we are working to understand the mechanisms of the most common and detrimental side effects of radiotherapy, and how these are influenced by medications or conditions in a patients life.
Tumour Microenvironment and Genetic Instability
Discover research in RadNet Manchester aiming to improve understanding of intra-tumour heterogeneity, radioresistance and metastasis.
National Proton Beam Therapy Hub
Discover how we are leveraging cutting edge infrastructure in Manchester to develop new treatments involving proton beam therapy.
Clinical Informatics Hub
Discover how this hub supports the capture, storage and use of routine real-time, real-world clinical outcomes to inform future research.